Confirmed great data from #8HW trial at #ESMO25 with the combination NIVO+IPI confirms the standard of care option in 1st line MSI-H/dMMR mCRC patients @oncodaily.bsky.social

Neo-adjuvantFOLFOX+/- #panitumumab for pts with KRAS-wt locally advanced #coloncancer: FOxTROT Trial www.annalsofoncology.org/article/S092... ➡️ @jenseligmann.bsky.social #GIonc @oncoalert.bsky.social

👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️
👉⬆️TOX G3 diarrhoea and rash

PD-1 blockade with Tislelizumab+chemoradiotherapy in unselected MMR locally advanced #rectalcancer
doi.org/10.1038/s415... @natmedicine.bsky.social
✅The pCR rates were 27.1%, 32.7% and 14.0% for experiment groups A and B and the control group C, respectively

Happy New Year to everyone! @oncodaily.bsky.social @oncoalert.bsky.social
@medicalwatch.bsky.social
@katesears.bsky.social

Find the results in the open access paper on #JCO @ascocancer.bsky.social at ascopubs.org/doi/pdf/10.1... #OncSky #GIonc

Find the results in the open access paper on #JCO @ascocancer.bsky.social at ascopubs.org/doi/pdf/10.1...

🙏🏻 Grateful to @medicalwatch.bsky.social and @katesears.bsky.social to promote the results of IMPROVE trial ascopubs.org/doi/pdf/10.1... in the weekly newsletter! To be always updated on most recent trials, you can subscribe at my.medical.watch/signup

#IMPROVE trial #Intermittent (I) or #Continuous (C) Panitumumab+FOLFIRI for First-Line Treatment of RAS/BRAF WT Metastatic Colorectal Cancer #oncsky #JCO

✅ Endpoint met
👉mPFS 11.2(C)vs17.5 months(I)
👉NO detrimental effect on OS
👉DCR 94.2%(C)vs91%(I)
👉Reduced toxicity
ascopubs.org/doi/pdf/10.1...